South San Francisco, CA, October 28, 2024 – FlemingMartin is pleased to announce that Alumis, a clinical-stage biopharmaceutical company developing novel oral therapies to treat immune-mediated diseases, has hired Dr. Elisa Muscianisi as Vice President of Clinical Development – Dermatology.
Elisa is a clinical development leader with 15 years of industry experience from a broad array of roles at Novartis. Her expertise in dermatology extends to leading and supporting large, complex, and global clinical trials spanning a range of indications, including Psoriasis, Hidradenitis suppurativa, and Lichen planus. Elisa joins Alumis after an impactful career at Novartis where she consistently earned promotions to roles of increasing scope and responsibility. Elisa prides herself on great agility – adapting quickly to new challenges that arise and excelling in problem resolution with calm, strategic thinking. Elisa is also very passionate about cross-functional collaboration and impacting patient care. She earned her MD from University of Insubria in Varese, Italy.
Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. Leveraging its proprietary precision data analytics platform, Alumis is building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases as monotherapy or combination therapies.